SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)
SANUWAVE Health (NASDAQ: SNWV) reported preliminary Q1 2025 revenues of $9.1-9.3 million, marking the highest Q1 revenue in company history. This represents a 57-61% increase compared to Q1 2024.
The company's UltraMIST product line showed exceptional performance with a 65% growth versus Q1 2024, contributing to approximately 99% of total revenues. The strong performance came despite a transition period involving new sales leadership and sales force restructuring.
The company manufactures all UltraMIST systems and applicators domestically, insulating it from current tariff concerns. Full Q1 2025 results are expected to be released around May 9, 2025.
SANUWAVE Health (NASDAQ: SNWV) ha riportato ricavi preliminari per il primo trimestre del 2025 di 9,1-9,3 milioni di dollari, segnando il più alto ricavo per il primo trimestre nella storia dell'azienda. Questo rappresenta un aumento del 57-61% rispetto al primo trimestre del 2024.
La linea di prodotti UltraMIST ha mostrato una performance eccezionale con una crescita del 65% rispetto al primo trimestre del 2024, contribuendo per circa il 99% dei ricavi totali. La forte performance è avvenuta nonostante un periodo di transizione che ha coinvolto un nuovo leadership nelle vendite e una ristrutturazione della forza vendita.
L'azienda produce tutti i sistemi e gli applicatori UltraMIST a livello nazionale, isolandosi così dalle attuali preoccupazioni tariffarie. I risultati completi del primo trimestre del 2025 sono attesi intorno al 9 maggio 2025.
SANUWAVE Health (NASDAQ: SNWV) reportó ingresos preliminares para el primer trimestre de 2025 de 9,1-9,3 millones de dólares, marcando el mayor ingreso del primer trimestre en la historia de la empresa. Esto representa un aumento del 57-61% en comparación con el primer trimestre de 2024.
La línea de productos UltraMIST mostró un rendimiento excepcional con un crecimiento del 65% en comparación con el primer trimestre de 2024, contribuyendo aproximadamente al 99% de los ingresos totales. Este sólido rendimiento se produjo a pesar de un período de transición que involucró un nuevo liderazgo en ventas y una reestructuración de la fuerza de ventas.
La empresa fabrica todos los sistemas y aplicadores UltraMIST a nivel nacional, aislándose así de las preocupaciones arancelarias actuales. Se espera que los resultados completos del primer trimestre de 2025 se publiquen alrededor del 9 de mayo de 2025.
SANUWAVE Health (NASDAQ: SNWV)는 2025년 1분기 예상 수익이 910만~930만 달러에 이를 것으로 보고하며, 이는 회사 역사상 가장 높은 1분기 수익을 기록한 것입니다. 이는 2024년 1분기 대비 57-61% 증가한 수치입니다.
회사의 UltraMIST 제품 라인은 2024년 1분기 대비 65% 성장하며 뛰어난 성과를 보였고, 전체 수익의 약 99%를 차지했습니다. 이러한 강력한 성과는 새로운 판매 리더십과 판매 팀의 재구성을 포함한 전환 기간에도 불구하고 이루어졌습니다.
회사는 모든 UltraMIST 시스템과 적용기를 국내에서 제조하여 현재의 관세 문제로부터 보호받고 있습니다. 2025년 1분기 전체 결과는 2025년 5월 9일경 발표될 예정입니다.
SANUWAVE Health (NASDAQ: SNWV) a annoncé des revenus préliminaires pour le premier trimestre 2025 de 9,1-9,3 millions de dollars, marquant le chiffre d'affaires le plus élevé pour un premier trimestre de l'histoire de l'entreprise. Cela représente une augmentation de 57-61% par rapport au premier trimestre 2024.
La gamme de produits UltraMIST a montré une performance exceptionnelle avec une croissance de 65% par rapport au premier trimestre 2024, contribuant à environ 99% des revenus totaux. Cette forte performance s'est produite malgré une période de transition impliquant un nouveau leadership des ventes et une restructuration de la force de vente.
L'entreprise fabrique tous les systèmes et applicateurs UltraMIST à l'échelle nationale, l'isolant ainsi des préoccupations tarifaires actuelles. Les résultats complets du premier trimestre 2025 devraient être publiés autour du 9 mai 2025.
SANUWAVE Health (NASDAQ: SNWV) meldete vorläufige Einnahmen für das erste Quartal 2025 von 9,1-9,3 Millionen Dollar, was die höchsten Einnahmen im ersten Quartal in der Unternehmensgeschichte darstellt. Dies entspricht einem Anstieg von 57-61% im Vergleich zum ersten Quartal 2024.
Die Produktlinie UltraMIST zeigte eine außergewöhnliche Leistung mit einem Wachstum von 65% im Vergleich zum ersten Quartal 2024 und trug etwa 99% zu den Gesamteinnahmen bei. Die starke Leistung kam trotz einer Übergangsphase mit neuer Verkaufsleitung und Umstrukturierung der Vertriebsorganisation.
Das Unternehmen stellt alle UltraMIST-Systeme und -Applikatoren im Inland her, wodurch es von aktuellen Zollbedenken isoliert ist. Die vollständigen Ergebnisse des ersten Quartals 2025 werden voraussichtlich am 9. Mai 2025 veröffentlicht.
- Record Q1 revenue of $9.1-9.3 million, up 57-61% year-over-year
- UltraMIST revenue grew 65% compared to Q1 2024
- Performance exceeded upper end of previous guidance
- Domestic manufacturing shields from tariff impacts
- Heavy revenue concentration (99%) in single product line UltraMIST
- Recent sales force restructuring and leadership changes indicate organizational flux
Insights
SANUWAVE Health's preliminary Q1 2025 revenue of
The revenue exceeding the upper end of management's previous guidance demonstrates strong execution and suggests the company may be gaining momentum in the wound care market. Their flagship product, UltraMIST, drove this performance with
While the strong growth trajectory is encouraging, the extreme concentration in a single product line presents a potential vulnerability. Having essentially all revenue tied to UltraMIST creates significant risk if any competitive, regulatory, or production challenges emerge for this product specifically.
The domestic manufacturing disclosure is strategically timed amid investor concerns about tariffs and international supply chain disruptions. This insulates SANUWAVE from current trade tensions and provides operational stability that many medical device competitors with international manufacturing might not enjoy.
Management's characterization of 2025 as a "breakout year" and reference to a "robust pipeline" signals confidence in sustaining this growth trajectory, though investors should watch for more concrete evidence in future quarters to confirm this optimism is warranted.
SANUWAVE is pleased to announce preliminary revenues of
Q1 2025 revenue increased between
UltraMIST revenues for Q1 2025 increased by more than
EDEN PRAIRIE, Minn., April 08, 2025 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the first quarter of 2025 are expected to be in the range of
“Sanuwave is pleased to announce a strong start to 2025, putting up our best Q1 in Company history,” said CEO Morgan Frank. “Q1 was a transition quarter as we moved to a new head of sales and restructured the sales force. I’m very proud of the team managing this without missing a beat. Our pipeline remains robust and consistent with 2025 being a breakout year for Sanuwave. The Company plans to release its full Q1 results on or around May 9, 2025 and we look forward to speaking with you then to give you a more complete update on our quarterly performance and our future plans and guidance.”
“Given the current trade climate and as we have received a number of questions from investors, I’d also like to take this opportunity to clarify that all manufacturing for the UltraMIST system and its applicators is performed domestically. Sanuwave does not anticipate any significant effects on production from the current tariff situation.”
The preliminary revenue results described herein are based on management’s initial analysis of the first quarter ended March 31, 2025, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
About SANUWAVE
SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
FAQ
What were SANUWAVE's (SNWV) Q1 2025 revenue numbers?
How much did SANUWAVE's UltraMIST revenue grow in Q1 2025?
When will SANUWAVE release full Q1 2025 financial results?
Is SANUWAVE affected by current tariff situations?
Did SANUWAVE meet its revenue guidance for Q1 2025?
